Compare KOP & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOP | LAB |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 488.4M |
| IPO Year | 2006 | 2011 |
| Metric | KOP | LAB |
|---|---|---|
| Price | $34.42 | $1.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $52.50 | $1.35 |
| AVG Volume (30 Days) | 130.9K | ★ 1.1M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,923,600,000.00 | $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.94 | N/A |
| P/E Ratio | $43.64 | ★ N/A |
| Revenue Growth | N/A | ★ 79.77 |
| 52 Week Low | $22.99 | $0.92 |
| 52 Week High | $35.61 | $1.72 |
| Indicator | KOP | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 82.58 | 30.39 |
| Support Level | $28.99 | $1.24 |
| Resistance Level | $31.88 | $1.46 |
| Average True Range (ATR) | 0.90 | 0.07 |
| MACD | 0.46 | -0.03 |
| Stochastic Oscillator | 92.33 | 1.25 |
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.